Point72 Asset Management
CYTK icon

Point72 Asset Management’s Cytokinetics CYTK Stock Holding History

Point72 Asset Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$135M Buy
1,587,712
+961,610
+154% +$69M 0.15% 140
2026
Q1 		$41.3M Buy
+626,102
New +$39.8M 0.05% 455
2025
Q4 		– Sell
-471,482
Closed -$29.3M – 3953
2025
Q3 		$25.9M Buy
+471,482
New +$19.4M 0.04% 467
2025
Q2 		– Sell
-1,722,984
Closed -$59.9M – 2269
2025
Q1 		$69.2M Buy
1,722,984
+1,553,071
+914% +$71.4M 0.16% 158
2024
Q4 		$7.99M Sell
169,913
-294,097
-63% -$15.3M 0.02% 772
2024
Q3 		$24.5M Buy
464,010
+89,162
+24% +$4.97M 0.06% 359
2024
Q2 		$20.3M Buy
374,848
+10,139
+3% +$612K 0.05% 400
2024
Q1 		$25.6M Buy
364,709
+207,609
+132% +$16.1M 0.06% 370
2023
Q4 		$13.1M Buy
+157,100
New +$5.69M 0.03% 596
2023
Q3 		– Sell
-160,400
Closed -$5.34M – 2534
2023
Q2 		$5.23M Buy
+160,400
New +$5.93M 0.02% 803
2023
Q1 		– Sell
-271,500
Closed -$12.4M – 2293
2022
Q4 		$12.4M Buy
271,500
+239,500
+748% +$10.3M 0.04% 481
2022
Q3 		$1.55M Buy
32,000
+12,367
+63% +$595K 0.01% 983
2022
Q2 		$771K Sell
19,633
-1,602,967
-99% -$64.5M ﹤0.01% 1127
2022
Q1 		$59.7M Buy
1,622,600
+737,146
+83% +$26.2M 0.24% 118
2021
Q4 		$40.4M Sell
885,454
-123,846
-12% -$4.78M 0.16% 169
2021
Q3 		$36.1M Buy
1,009,300
+681,800
+208% +$20.1M 0.16% 161
2021
Q2 		$6.48M Sell
327,500
-47,100
-13% -$1.11M 0.03% 548
2021
Q1 		$8.71M Sell
374,600
-791,694
-68% -$16.9M 0.04% 457
2020
Q4 		$24.2M Sell
1,166,294
-440,056
-27% -$8.04M 0.12% 237
2020
Q3 		$34.8M Buy
1,606,350
+1,278,073
+389% +$29.9M 0.18% 153
2020
Q2 		$7.74M Sell
328,277
-462,923
-59% -$8.68M 0.05% 393
2020
Q1 		$9.33M Sell
791,200
-2,237,551
-74% -$28.5M 0.08% 315
2019
Q4 		$32.1M Buy
3,028,751
+2,594,651
+598% +$26.7M 0.17% 178
2019
Q3 		$4.94M Sell
434,100
-172,900
-28% -$2.17M 0.03% 461
2019
Q2 		$6.83M Buy
+607,000
New +$5.85M 0.04% 449

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Point72 Asset Management's CYTK Position: Q2 2026 in Review

Point72 Asset Management increased its Cytokinetics (CYTK) stake by 154% in Q2 2026, buying an estimated $69M and bringing the position to 1,587,712 shares worth $135M. The position accounts for 0.15% of the portfolio, ranked #140.

Point72 Asset Management first reported a position in CYTK in Q2 2019 and has held it in 25 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Point72 Asset Management held 1,587,712 shares of Cytokinetics worth $135M as of Q2 2026.
  • Point72 Asset Management bought 961,610 Cytokinetics shares in Q2 2026, an estimated $69M.
  • Cytokinetics made up 0.15% of Point72 Asset Management's portfolio in Q2 2026, its #140 holding.
  • Point72 Asset Management first reported a position in Cytokinetics in Q2 2019 and has held it in 25 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.